LABGENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,625 KRW | -2.05% |
|
-1.32% | -31.91% |
| Sales 2024 * | 111B 81.03M | Sales 2025 * | 147B 107M | Capitalization | 195B 142M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.92 x |
| Net cash position 2024 * | 93B 67.7M | Net cash position 2025 * | 99B 72.07M | EV / Sales 2025 * | 0.65 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.05% | ||
| 1 week | -1.32% | ||
| Current month | -13.51% | ||
| 1 month | -18.10% | ||
| 3 months | -27.29% | ||
| 6 months | -32.95% | ||
| Current year | -31.91% |
1 week
2 510.00
2 720.00
1 month
2 510.003 380.00
Current year
2 510.004 265.00
1 year
2 510.006 500.00
3 years
2 510.007 000.00
5 years
663.339 633.33
10 years
663.339 633.33
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Hyun Jin
CEO | Chief Executive Officer | 56 | 02-03-28 |
Myung-Shin Kim
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-03-31 |
Yong-Sik Won
COO | Chief Operating Officer | 51 | 09-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Hyun Jin
CEO | Chief Executive Officer | 56 | 02-03-28 |
Sung-Yong Ahn
BRD | Director/Board Member | 55 | 17-03-27 |
Won-Hui Hwang
BRD | Director/Board Member | 58 | 22-03-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2,625 | -2.05% | 564 805 |
| 24-04-18 | 2,680 | +4.28% | 709,546 |
| 24-04-17 | 2,570 | +1.58% | 384,793 |
| 24-04-16 | 2,530 | -2.32% | 734,841 |
| 24-04-15 | 2,590 | -2.08% | 944,393 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
LabGenomics Co., Ltd is a Korea-based company engaged in the provision of in vitro diagnostic (IVD) services. The Company mainly provides IVD services, including general diagnostic check services, molecular diagnostic check services, and research and development services. The Companyâs IVD products include deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) kits and others. It also provides examination for breast cancer and colorectal cancer, biosensor for point of care testing (POCT) and others. It also provides healthy food.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.91% | 145M | |
| -18.11% | 8.02B | |
| +33.79% | 3.51B | |
| -29.02% | 2.97B | |
| -7.71% | 2.48B | |
| -14.30% | 2.23B | |
| -16.38% | 1.76B | |
| -22.17% | 1.44B | |
| -39.69% | 1.25B | |
| -11.20% | 1.11B |
- Stock Market
- Equities
- A084650 Stock
